Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.57 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | STS | P08842 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5215842 | 0.82 | AVPR1A (0.59) | BRD4AVPR1ATHRBSMN1; SMN2GAA | |
| SCHEMBL5762606 | 0.82 | THRB (0.54) | BRD4THRBSMN1; SMN2GAAGPR119 | |
| SCHEMBL5761938 | 0.77 | THRB (0.54) | BRD4THRBSMN1; SMN2GAAGPR119 | |
| SCHEMBL4343857 | 0.76 | HPGDS (0.55) | BRD4THRBSMN1; SMN2GAAGPR119 | |
| SCHEMBL10189899 | 0.76 | MEN1 (0.56) | AVPR1ATHRBSMN1; SMN2GAAGPR119 | |
| SCHEMBL10189920 | 0.76 | GPR119 (0.52) | AVPR1ATHRBSMN1; SMN2GAAGPR119 | |
| SCHEMBL14514081 | 0.75 | SMN1; SMN2 (0.70) | BRD4THRBSMN1; SMN2GAAGPR119 | |
| SCHEMBL3843148 | 0.74 | NAMPT (0.66) | THRBSMN1; SMN2GAAGPR119TP53 | |
| SCHEMBL7550572 | 0.74 | GPR119 (0.49) | THRBSMN1; SMN2GAAGPR119TP53 | |
| SCHEMBL3844975 | 0.74 | CCR1 (0.64) | GAATP53MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558598-B1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | PFIZER LTD (GB) | 2007-07-18 | — | — | EP | disclosed |
| US-7084145-B2 | Triazole compounds useful in therapy | PFIZER INC. (US) | 2006-08-01 | — | — | US | disclosed |
| US-20040162278-A1 | Triazole compounds useful in therapy | PFIZER INC | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162278-A1 | Triazole compounds useful in therapy | AVPR2, AVPR1B, AVPR1A | BRD4 905/4885AVPR1A 3/4885THRB 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.